|AHFS/Drugs.com||Micromedex Detailed Consumer Information|
|Drug class||Typical antipsychotic|
|Elimination half-life||24 to 48 hours|
|Excretion||Biliary and renal|
|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||386.57 g·mol−1|
|3D model (JSmol)|
|Melting point||130 °C (266 °F)|
|Solubility in water||insoluble mg/mL (20 °C)|
Mesoridazine (Serentil) is a piperidine neuroleptic drug belonging to the class of drugs called phenothiazines, used in the treatment of schizophrenia. It is a metabolite of thioridazine. The drug's name is derived from the methylsulfoxy and piperidine functional groups in its chemical structure.
It has central antiadrenergic, antidopaminergic, antiserotonergic and weak muscarinic anticholinergic effects.
Serious side effects include akathisia, tardive dyskinesia and the potentially fatal neuroleptic malignant syndrome.
Mesoridazine was withdrawn from the United States market in 2004 due to dangerous side effects, namely irregular heart beat and QT-prolongation of the electrocardiogram.
It currently appears to be unavailable worldwide.
(TCAs and TeCAs)